A Phase 4 interventional study of Mavyret in Hepatitis C, Kidney Transplant; Complications and Heart Transplant Infection, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing glecaprevir and pibrentasvir in Hepatitis C — 3 open to participants now, 3 under way, 1 of them phase 3. glecaprevir and pibrentasvir · Hepatitis C.
Among the 43 studies testing glecaprevir and pibrentasvir in Hepatitis C, this one is the 10th largest by enrollment, is one of 4 that started in 2020, is one of 10 in phase 4, and was the 34th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →3 of the 43 studies testing glecaprevir and pibrentasvir in Hepatitis C are open now, in 2 countries. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 16–45 · Women only
White River Junction Veterans Affairs Medical Center · Sites in United States
Ages 19–70
Kirby Institute · Sites in Australia
Ages 18+
By country, each count listing its studies:
glecaprevir and pibrentasvir: first FDA approval 2017 (MAVYRET), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 27 · Phase 4 10
First in 2014; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 43 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 5 studies filed under Hepatitis C — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing glecaprevir and pibrentasvir in Hepatitis C, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study were all recipients of HCV viremic organs will receive combination therapy.
Drug: Mavyret
Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
Also known as: Zetia
Rate of Prevention of HCV Viremia in Recipients of HCV Viremic Solid Organs
The percentage of patients who did not become HCV viremic using this preemptive treatment protocol.
Time frame: 3 months
Graft and Patient Survival
The number of subjects alive at 1-year and the number of subjects with a functioning transplanted organ (graft survival) at 1-year.
Time frame: 1 year
| Milestone | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| Started | 227 |
| Completed | 227 |
| Not completed | 0 |
The percentage of patients who did not become HCV viremic using this preemptive treatment protocol.
| percentage of patients | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| Rate of Prevention of HCV Viremia in Recipients of HCV Viremic Solid Organs | 99.6 |
The number of subjects alive at 1-year and the number of subjects with a functioning transplanted organ (graft survival) at 1-year.
| Participants | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| Graft Survival | 222 |
| Patient Survival | 219 |
Collected over Adverse events were collected from the start of study drug administration through 30 days after the last dose of study drug (approximately 37 days total). Deaths were assessed up to 1 year.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Pre-emptive Treatment Arm | 8/227 (3.5%) | 0/227 (0%) | 0/227 (0%) |
| Age, Continuous(years) | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| Mean | 60 (52 to 68) |
| Sex: Female, Male(Participants) | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| Female | 75 |
| Male | 152 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 227 |
| Race (NIH/OMB)(Participants) | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| American Indian or Alaska Native | 8 |
| Asian | 24 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 39 |
| White | 116 |
| More than one race | 0 |
| Unknown or Not Reported | 39 |
| Region of Enrollment(participants) | Arm 1: Pre-emptive Treatment Arm |
|---|---|
| United States | 227 |
Plan to share: No
Ran from Sep 2020 to primary completion in Nov 2025, 61 months.
Results were first posted in Oct 2026, 11 months after primary completion.
Of 56 non-industry phase 4 interventional studies under Hepatitis C, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 61 months is above that.
Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 16 and three quarters within 48.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Nov 2025, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glecaprevir and pibrentasvir